In clinical diagnostics, peripheral blood is often treated as a "window" into the body’s health. It is accessible, minimally invasive, and circulates through nearly every tissue. However, a growing body of research suggests that this window is frequently clouded. Across diverse conditions—from Alzheimer’s disease and psychosis to asthma and heart failure—researchers are finding a profound "disconnect" between the molecular signals found in systemic circulation and the actual pathological environment of the affected organ.
Understanding why this discrepancy exists is critical for the next generation of precision medicine. If we cannot trust systemic markers to reflect localized reality, our diagnostic tools will remain blunt and our treatments poorly timed.
The Barrier Problem
The most significant driver of this disconnect is the presence of physiological barriers, most notably the blood-brain barrier (BBB). The BBB is a highly selective filter designed to protect the central nervous system (CNS) from fluctuations in systemic chemistry. While this protection is vital for neural function, it creates a "black box" for diagnostics.
Harald Hampel and colleagues argue in A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease that the failure of many anti-inflammatory trials in Alzheimer’s stems from this gap. Markers measured in the blood often fail to represent the complex, localized immune environment of the brain. Similarly, Burcu F. Darst and Corinne D. Engelman demonstrated that the selective permeability of the BBB results in a near-total lack of correlation between metabolic profiles in the blood and those in the cerebrospinal fluid (CSF).
This is not limited to the brain. In respiratory health, Junxiang Chen and Adel Boueiz have noted that systemic gene expression in the blood may not accurately represent the localized inflammatory processes occurring within lung tissues in COPD. The body is not a single, well-mixed beaker; it is a collection of distinct compartments.
Signal Attenuation and Localized Degradation
Even when a biomarker is produced at the site of a disease, it may never reach the bloodstream in a detectable or representative form. Bing He and Lana X. Garmire highlight this in the context of cancer, where a significant discrepancy exists between the concentration of a biomarker within a tumor and its presence in the blood. This "signal attenuation" can be caused by localized degradation or simply inefficient release into the circulation.
In cardiovascular research, Olivia Ziegler and Jun Feng found that metabolic changes within heart tissue, such as elevated oxidative stress markers, are often completely invisible in systemic blood samples. This suggests that relying solely on blood-based indicators can lead clinicians to significantly underestimate the severity of localized tissue distress.
The Noise of Passive Diffusion
The inverse problem also exists: sometimes a marker appears in a localized fluid not because it was produced there, but because it leaked in from the blood. Jaume Trapé and Francesc Sant addressed this in their study of ascitic fluid. They found that high concentrations of tumor markers in localized body fluids can result from passive diffusion from the bloodstream.
To solve this, they proposed using a fluid-to-serum (F/S) ratio. By comparing the concentration in the localized fluid to the concentration in the blood, researchers can filter out "systemic noise" and determine if a marker represents a true localized pathological signal.
Bridging the Gap with Comparative Profiling
The path forward involves moving away from "one-size-fits-all" blood tests and toward comparative profiling—measuring markers in multiple compartments simultaneously to understand their relationship.
For example, Stéphanie Debette and Shinichi Namba used proteogenomics across both CSF and plasma to identify a "biological fingerprint" of cerebral small vessel disease. By looking at both fluids, they could pinpoint which proteins were actually driving brain pathology versus those that were merely systemic bystanders.
In psychiatry, where the disconnect is particularly acute, Tianhong Zhang and Jiahui Zeng have shown that specific serum complement proteins (C5 and C5a) are better predictors of psychosis than general inflammatory cytokines, likely because they more closely mirror the localized mechanisms of synaptic pruning in the brain.
Precision Through Multimodal Integration
The ultimate goal is to integrate these disparate signals. Junxiang Chen and colleagues demonstrated the power of "multimodal" AI by bridging macro-scale medical imaging (CT scans) with micro-scale molecular data (RNA sequencing). This approach allows researchers to see the localized damage (via imaging) while simultaneously identifying the systemic signatures that correlate with it.
By acknowledging that the blood is an imperfect mirror, researchers like M. Binvignat are now focusing on how blood-borne immune signals specifically diverge from local inflammation (such as in joint tissue in Rheumatoid Arthritis). Understanding this divergence is not a failure of the biomarker; it is the key to understanding the disease's geography. Only by mapping the distance between the systemic signal and the localized source can we achieve true precision in medicine.